OLIVIA DIZON: Open Payments
NPI 1346096575 · QUEENSTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$818 in 41 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $213 · 2025 $818
Food & beverage: $818
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $168 |
| PFIZER INC. | 7 | $141 |
| Merck Sharp & Dohme LLC | 4 | $107 |
| Astellas Pharma US Inc | 3 | $84 |
| Exact Sciences Corporation | 3 | $54 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $46 |
| AstraZeneca Pharmaceuticals LP | 2 | $43 |
| Dexcom, Inc. | 1 | $23 |
| Insulet Corporation | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
Products named: GARDASIL 9, Wegovy, Veozah, ELIQUIS, The Cologuard Plus Collection Kit, XIFAXAN, NURTEC ODT, Ozempic.
Industry payments across MD — which companies pay providers there.
